EGFR signaling contributes to acquired resistance to CDK4/6 inhibitors in ER plus breast cancer cells in vitro and in vivo

被引：0
|
作者：
Lypova, Nadiia
Lanceta, Lilibeth
Daugherty, Susan
Chesney, Jason
Imbert-Fernandez, Yoannis
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P1-13-18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-13-18
引用
收藏
页数：2
相关论文
共 50 条
  • [41] RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER plus breast cancer
    Kindt, Charlotte K.
    Ehmsen, Sidse
    Traynor, Sofie
    Policastro, Benedetta
    Nissen, Nikoline
    Jakobsen, Mie K.
    Hundebol, Monique F.
    Johansen, Lene E.
    Bak, Martin
    Arbajian, Elsa
    Staaf, Johan
    Ditzel, Henrik J.
    Alves, Carla L.
    FRONTIERS IN ONCOLOGY, 2025, 14
  • [42] Proteogenomic characterization of CDK4/6 inhibitor-resistant ER plus breast cancer
    Chen, Christopher T.
    Leshchiner, Ignaty
    Martin, Liz
    Kane, Harry
    Rhrissorrakrai, Kahn
    Utro, Filippo
    Levovitz, Chaya
    Gillette, Michael
    Satpathy, Shankha
    Pinto, Christopher
    McLoughlin, Daniel
    Allen, Read
    Danysh, Brian P.
    Slowik, Kara
    Jacobs, Raquel A.
    Carr, Steven
    Parida, Laxmi
    Getz, Gad
    Juric, Dejan
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [43] Mechanisms of Resistance to CDK4/6 Inhibitors in Hormone Receptor-Positive (HR plus ) Breast Cancer: Spotlight on Convergent CDK6 Upregulation and Immune Signaling
    Brett, Jamie O.
    Herman, Paige E.
    Mayer, Erica L.
    Bardia, Aditya
    Wander, Seth A.
    CURRENT BREAST CANCER REPORTS, 2022, 14 (04) : 222 - 232
  • [44] Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
    María Jimena Rodriguez
    María Cecilia Perrone
    Marina Riggio
    Marta Palafox
    Valeria Salinas
    Andrés Elia
    Natali Daiana Salgueiro
    Andrea Eugenia Werbach
    María Paula Marks
    Marcelo A. Kauffman
    Luciano Vellón
    Violeta Serra
    Virginia Novaro
    Scientific Reports, 13
  • [45] CDK4/6 inhibitors in breast cancer - from in vitro models to clinical trials
    Saleh, Lubaid
    Wilson, Caroline
    Holen, Ingunn
    ACTA ONCOLOGICA, 2020, 59 (02) : 219 - 232
  • [46] Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
    Rodriguez, Maria Jimena
    Perrone, Maria Cecilia
    Riggio, Marina
    Palafox, Marta
    Salinas, Valeria
    Elia, Andres
    Salgueiro, Natali Daiana
    Werbach, Andrea Eugenia
    Marks, Maria Paula
    Kauffman, Marcelo A.
    Vellon, Luciano
    Serra, Violeta
    Novaro, Virginia
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [47] Combination of ZEN-3694 with CDK4/6 inhibitors reverses resistance in ER-positive breast cancer
    Kharenko, Olesya A.
    Patel, Reena G.
    Calosing, Cyrus
    van der Horst, Edward H.
    CANCER RESEARCH, 2020, 80 (16)
  • [48] Carboxypeptidase vitellogenic like facilitates resistance to CDK4/6 inhibitors in breast cancer
    Zhu, Xiang
    Xu, Xiaojie
    Zhang, Lin
    Yang, Xuhui
    THORACIC CANCER, 2023, 14 (11) : 983 - 991
  • [49] Improving Breast Cancer Therapy With CDK4/6 Inhibitors
    Jaganathan, Hamsa
    Overstreet, Karen
    Reed, Elizabeth
    CLINICAL BREAST CANCER, 2014, 14 (06) : 379 - 380
  • [50] Predicting Response to CDK4/6 Inhibitors in Breast Cancer
    Schultz, Emily
    Hamilton, Deanna
    Wang, Jianxin
    Witkiewicz, Agnieszka
    LABORATORY INVESTIGATION, 2023, 103 (03) : S208 - S208
12345